CANF · Can-Fite BioPharma Ltd.

Can-Fite BioPharma is progressing its pancreatic cancer program based on encouraging Phase 2a results for Namodenoson monotherapy in advanced pancreatic adenocarcinoma patients post prior therapy. Key Phase 2a outcomes include a favorable safety profile, clinical activity with stable disease in over 30% of evaluable patients, 35% still on therapy, and notably prolonged treatment exceeding 16 months in some cases. This supports advancement to a Phase 2b trial combining Namodenoson with immunotherapy to evaluate progression-free survival, overall survival, disease stabilization, and other efficacy endpoints. Dr. Salomon Stemmer, the Phase 2a principal investigator and oncology expert at Rabin Medical Center, highlighted Namodenoson's safety and potential synergy with chemotherapy in this high-unmet-need malignancy with limited options. Investor interest is heightened by planned discussions of the Phase 2b design at the BIO International Convention, where VP Business Development Dr. Sari Fishman will engage leading oncology firms. The company has secured confidentiality agreements with several pharmaceutical partners assessing collaboration on the program. Namodenoson's Orphan Drug Designation from the FDA underscores regulatory recognition for pancreatic cancer, alongside its evaluation in liver cancer trials. This development milestone de-risks the asset and positions Can-Fite for potential partnerships in oncology.